Search Results - "Svane, I.M."

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma by Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

“…Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration…”
Get full text

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer by Geukes Foppen, M.H., Donia, M., Svane, I.M., Haanen, J.B.A.G.

“…Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic…”
Get full text

2546 Predictors of chemotherapy induced toxicity in 421 patients with metastatic castration-resistant prostate cancer - results from a single institution by Kongsted, P, Svane, I.M, Lindberg, H, Sengeloev, L

Get full text

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma by Kverneland, A.H., Thorsen, S.U., Granhøj, J.S., Hansen, F.S., Konge, M., Ellebæk, E., Donia, M., Svane, I.M.

“…Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not…”
Get full text

Cellular based cancer vaccines: type 1 polarization of dendritic cells by Hansen, M, Met, Ö, Svane, I M, Andersen, M H

“…Cancer vaccines designed to re-calibrate the existing host-tumour interaction, tipping the balance from tumor acceptance towards tumor control holds huge…”
Get more information

EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL) by Ascierto, P, Bastholt, L, Mohr, P, Hoeller, C, Robert, C, Larkin, J, Dummer, R, Ekbom, A, Chiarion-Sileni, V, Dutriaux, C, Mortier, L, Neyns, B, Nyakas, M, Garbe, C, Baurain, J.F, Kruse, V, Svane, I.M, Alfaya, L, Ciria, C, Blank, C

Get full text

9329 POSTER PET Scans as Evaluation of DC Vaccinations in Patients With Malignant Melanoma by Enqell-Norreqárd, L, Alslev, L, Johannesen, H.H, Hendel, H.W, Svane, I.M

Get full text

Tumour Infiltrating Lymphocytes (Til) and Their Use in Therapy by Svane, I.M.

Get full text

58INTUMOUR INFILTRATING LYMPHOCYTES (TIL) AND THEIR USE IN THERAPY by Svane, I.M.

“…Abstract During the last decade the field of cancer therapy has been reformed by the development of new and effective treatment modalities with a major focus…”
Get full text

81P Clinical value of routine FDG-PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma by Ellebaek, E., Donia, M., Svane, I.M., Andersen, R., Hendel, H.W.

Get full text

1078P Real-world data on patients with melanoma brain metastases and outcome related to locoregional treatment modalities and systemic therapy by Pedersen, S., Møller, S., Donia, M., Persson, G.F., Svane, I.M., Ellebaek, E.

Get full text

Combined Detection of CD137 and Type 1 Functions Improves Identification and Characterization of the Activated T Lymphocyte Repertoire by Draghi, A., Gokuldass, A., Chamberlain, C.A., Radic, H.D., Svane, I.M., Donia, M.

Get full text

Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment by Willumsen, N., Bager, C.L., Jensen, C., Karsdal, M.A., Madsen, D.H., Hansen, M., Schmidt, H., Svane, I.M.

Get full text

1250P - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment by Willumsen, N., Bager, C.L., Jensen, C., Karsdal, M.A., Madsen, D.H., Hansen, M., Schmidt, H., Svane, I.M.

“…The extracellular matrix (ECM) is a major component of tumors. Several recent findings link ECM composition with outcome in cancer patients treated with immune…”
Get full text

Predictors of responses to immune checkpoint blockade in advanced melanoma by Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., Weide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dréno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, J. S., Eggermont, A. M., Zitvogel, L.

“…Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune…”
Get full text

1685P COLAR: Results from an intervention study investigating IL-6 blockade with tocilizumab for treatment of immune checkpoint inhibitor induced colitis and arthritis by Holmstrøm, R.B., Nielsen, O.H., Jacobsen, S., Riis, L.B., Theile, S., Bjerrum, J.T., Vilmann, P., Johansen, J.S., Boisen, M.K., Eefsen, R.L., Svane, I.M., Nielsen, D., Chen, I.M.

Get full text

1071P A nationwide, real-life study of outcome and quality of life after the introduction of adjuvant immunotherapy for Danish melanoma patients by Ellebaek, E., Holmstrøm, R.B., Ruhlmann, C.H., Schmidt, H., Haslund, C.A., Donia, M., von Heymann, A., Johansen, C., Bastholt, L., Svane, I.M.

Get full text

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges by Saini, K.S., Svane, I.M., Juan, M., Barlesi, F., André, F.

Get full text

P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit? by Kongsted, P, Svane, I.M, Daugaard, G, Lindberg, H, Sengeløv, L

Get full text

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression by Andersen, R., Borch, T.H., Draghi, A., Gokuldass, A., Rana, M.A.H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J.W., Westergaard, M.C.W., Radic, H.D., Chamberlain, C.A., Hölmich, L.R., Hendel, H.W., Larsen, M.S., Met, Ö, Svane, I.M., Donia, M.

“…Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study,…”
Get full text